Elizabeth Gerard, MD: Explaining the Breastfeeding Gap In Epilepsy
January 23rd 2020The associate professor of neurology and director of the Women With Epilepsy Program at Northwestern University Feinberg School of Medicine detailed the ongoing questions about assessing the gaps in breastfeeding between women with, and without, epilepsy.
Transcutaneous Stimulation Device Shows Rapid Acute Migraine Relief In ED
January 23rd 2020The Headaterm TENS device was shown to decrease pain at an 11.8% better rate than many acute migraine medications used in the emergency department in randomized trials, with data suggesting it is both effective and fast-acting.
Elizabeth Gerard, MD: Successful Breastfeeding in Women With Epilepsy
January 22nd 2020The associate professor of neurology and director of the Women With Epilepsy Program at Northwestern University Feinberg School of Medicine spoke about the findings of the MONEAD study and their implications for women with epilepsy.
The Potential of Gene Therapy to Treat SCN1A-Positive Epilepsy
January 22nd 2020The medical director of the Comprehensive Epilepsy Clinic at Nicklaus Children’s Hospital shared his insight into the potential of using an SCN1A-targeted adeno-associated viral vector-based gene therapy in epilepsy.
Elizabeth Gerard, MD: Advising Women With Epilepsy to Breastfeed
January 21st 2020The associate professor of neurology and director of the Women With Epilepsy Program at Northwestern University Feinberg School of Medicine spoke about the need for consistency in the messaging conveyed to women with epilepsy who are having children.
Patients With Stroke Who Have Favorable Imaging Profiles Have Better Functional Outcomes
January 21st 2020Those who have strokes with favorable imaging profiles have a higher likelihood of receiving endovascular thrombectomy as well as achieving high functional independence rates after 90 days.
Siponimod Gets Green Light for Secondary Progressive MS in the EU
January 20th 2020As was the case for siponimod’s FDA approval in March 2019, this regulatory decision by the European Commission for the selective sphingosine-1-phosphate receptor modulator was based on the phase 3 EXPAND trial.
Opting for Epilepsy Surgery: How a Risk Assessment Tool Can Help Provide Expectations
January 17th 2020Lara Jehi, MD, professor of neurology and an epilepsy specialist at the Cleveland Clinic Lerner College of Medicine, detailed the process and decisions that patients with epilepsy face when considering surgery.
Corticosteroid Alternative Demonstrates High Rate of MS Relapse Resolution
January 16th 2020Findings from a large scale study of multiple sclerosis treatments showed greater levels of relapse resolution with oral corticosteroids and repository corticotropin injections compared to other treatments.
Will Gepants and Monoclonal Antibodies Be Used in Tandem for Migraine?
January 16th 2020After first-step data suggested that one small molecule CGRP receptor antagonist and a monoclonal antibody against CGRP were successful and safe together in migraine. One of the study authors, Kathleen Mullin, MD, discussed the data.
Relief for MS Drug Prices Is Not Coming Soon, Report Suggests
January 16th 2020New data from a report on US Medicaid program spending suggests that spending on disease-modifying therapies has more than doubled over a recent 7-year stretch, with no expected help from generic competition coming soon.
Tapping Into Individualized Risk Prediction in Epilepsy Surgery Candidates
January 15th 2020Lara Jehi, MD, professor of neurology and an epilepsy specialist at the Cleveland Clinic Lerner College of Medicine, spoke to her work on individualized risk assessments for epilepsy surgery candidates and the impact it can have for both physicians and patients alike.